Children’s Hospital Los Angeles Joins Multi-Center Trial for In Vivo CRISPR Gene Editing Therapy for Sickle Cell Disease

August 17, 2026

Children’s Hospital Los Angeles (CHLA) Facebook USA

Overview

Children’s Hospital Los Angeles (CHLA) has announced its participation in a multi-center clinical trial evaluating a novel CRISPR-based, direct gene editing therapy for sickle cell disease. Unlike existing FDA-approved gene therapies that modify autologous hematopoietic stem cells ex vivo, this new trial explores an in vivo approach to directly edit the disease-causing gene within the patient. This aims for a less invasive treatment that could more efficiently alleviate complications of sickle cell disease and broaden treatment access.

In Depth

Key Findings

Children’s Hospital Los Angeles (CHLA) has announced its significant involvement as a leading site in a multi-center clinical trial evaluating a novel gene therapy approach for sickle cell disease (SCD). This groundbreaking trial leverages CRISPR gene-editing technology to directly modify the disease-causing gene within the patient’s body (in vivo). This represents a departure from existing FDA-approved gene therapies, which require ex vivo cellular manipulation, potentially offering a more direct and less invasive therapeutic option for SCD patients.

Technical and Clinical Details

Sickle cell disease is a hereditary blood disorder caused by a specific mutation in the beta-globin gene, leading to the production of abnormal hemoglobin S (HbS). This results in misshapen, sickle-shaped red blood cells that can obstruct blood flow, causing severe vaso-occlusive crises and organ damage. While many current FDA-approved gene therapies involve an ex vivo approach—harvesting a patient’s hematopoietic stem cells, genetically modifying them using viral vectors or CRISPR technology outside the body, and then reinfusing them—this new CRISPR-based therapy under investigation aims for direct in vivo gene editing. This approach involves delivering the gene-editing tools directly into the patient’s body, targeting specific cell populations, in this case, hematopoietic stem cells, for genetic correction. If successful, this method could eliminate the need for myeloablative conditioning (pre-treatment chemotherapy) and complex ex vivo cell processing, significantly simplifying the treatment regimen. This simplification would potentially make the therapy more accessible to a broader patient population. The initial phases of the trial will primarily assess the safety of the in vivo gene editing and the efficiency of the genetic modification within the target cells.

Background and Industry Context

The treatment landscape for sickle cell disease has seen remarkable progress in recent years, particularly with the advent of gene therapies. However, current gene therapies remain costly, require complex procedures, and are only available at highly specialized medical centers. In vivo gene editing is gaining substantial attention as a next-generation approach to overcome these limitations. Direct editing within the patient’s body is expected to shorten treatment times, potentially reduce healthcare costs, and expand the number of patients who can access these life-changing therapies. The participation of a prominent institution like CHLA in this multi-center trial underscores the credibility and transformative potential of this innovative approach, signaling a new direction in the treatment of pediatric genetic disorders.

Strategic Significance and Outlook

The progress of this multi-center trial is paramount for the future of sickle cell disease treatment. If in vivo CRISPR gene editing demonstrates both safety and efficacy, it would represent a significant paradigm shift in the management of genetic diseases. Future steps will involve evaluating long-term safety and efficacy in larger patient cohorts, alongside continuous efforts to further minimize the risk of off-target edits. Successful outcomes could provide SCD patients with a safer, more accessible, and potentially curative treatment option, dramatically improving the quality of life for millions worldwide. Furthermore, the establishment of a robust in vivo gene editing platform technology would pave the way for similar therapeutic developments across a wide range of other genetic disorders.

Source: https://www.facebook.com/ChildrensLA/posts/fda-approved-gene-therapies-can-significantly-reduce-complications-of-sickle-cel/1498002365690368/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.